title: Orlistat for obesity: benefits beyond weight loss.
abstract: Orlistat lowers lipids and improves insulin sensitivity, but its effect on other metabolic syndrome related parameters is not known. To assess its influence on adiponectin, high sensitive C-reactive protein (hs-CRP) and other metabolic syndrome related parameters, this study enrolled 106 participants in a weight-reduction program and categorized them into a group of 51 who had been treated with orlistat 360 mg/day for one year and a group of 55 age and sex and body mass index (BMI) matched controls. The orlistat group had greater changes in BMI, % body fat (% BF), waist circumference, and insulin resistance, hs-CRP, leptin and adiponectin levels after one year on the program than the controls. After adjusting for % BF and waist circumference, change of serum leptin and adiponectin levels remained significantly different. It was found that orlistat could effectively manage obesity related co-morbidities, especially insulin resistance and atherosclerosis risk. It decreases leptin and increases adiponectin independent of % BF and waist circumference. Therefore, orlistat appears to have anti-diabetic and anti-atherogenic properties and may help prevent metabolic syndrome in the overweight people.
authors.affiliation: Division of Edocrinology and Metabolosm, Department of Internal Medicine, Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung Hsien 83305, Taiwan. c2607c@ms56.hinet.net
authors.forename: Ching-Jung
authors.initials: CJ
authors.lastname: Hsieh
authors.forename: Pei-Wen
authors.initials: PW
authors.lastname: Wang
authors.forename: Rue-Tsuan
authors.initials: RT
authors.lastname: Liu
authors.forename: Shih-Chen
authors.initials: SC
authors.lastname: Tung
authors.forename: Wen-Yen
authors.initials: WY
authors.lastname: Chien
authors.forename: Jung-Fu
authors.initials: JF
authors.lastname: Chen
authors.forename: Chen-Hsiong
authors.initials: CH
authors.lastname: Chen
authors.forename: Ming-Chun
authors.initials: MC
authors.lastname: Kuo
authors.forename: Ya-Hui
authors.initials: YH
authors.lastname: Hu
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000517:prevention & control; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus / Q000517:prevention & control; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007783:Lactones / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology*
chemical_list: D019440:Anti-Obesity Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007783:Lactones; D008074:Lipoproteins; D002097:C-Reactive Protein; D000077403:Orlistat; D002784:Cholesterol